Damien Fink
Overview
Explore the profile of Damien Fink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chialastri A, Hoffman H, Fink D, Dashnau J
Cytotherapy
. 2024 Jul;
26(11):1341-1352.
PMID: 39023463
Background Aims: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated genome editing (GE) components (e.g., nucleases, guide RNAs (gRNAs), and plasmids) are used to genetically modify cells during development of ex...
2.
Girgis S, Wang Lin S, Pillarisetti K, Verona R, Vieyra D, Casneuf T, et al.
Blood Adv
. 2022 Aug;
7(4):644-648.
PMID: 36006441
No abstract available.
3.
Yao Z, Loggia L, Fink D, Chevrier M, Marciniak S, Sharma A, et al.
Clin Drug Investig
. 2020 Oct;
40(12):1127-1136.
PMID: 33085033
Background: The interferon (IFN) pathway has been correlated with clinical and serological markers of disease activity in patients with systemic lupus erythematosus (SLE). Objective: The pharmacokinetics and pharmacodynamics of JNJ-55920839,...
4.
Zheng S, Niu J, Geist B, Fink D, Xu Z, Zhou H, et al.
MAbs
. 2020 Sep;
12(1):1813962.
PMID: 32967523
Biotherapeutic drugs against tumor necrosis factor (TNF) are effective treatments for moderate to severe inflammatory bowel disease (IBD). Here, we evaluated CNTO 5048, an antimurine TNF surrogate monoclonal antibody (mAb),...
5.
Zheng S, Shen F, Jones B, Fink D, Geist B, Nnane I, et al.
MAbs
. 2020 Jun;
12(1):1770018.
PMID: 32544369
Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). JNJ-61178104 is a novel...
6.
Nnane I, Frederick B, Yao Z, Raible D, Shu C, Badorrek P, et al.
Br J Clin Pharmacol
. 2020 May;
86(12):2507-2518.
PMID: 32415720
Aims: To assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 7160, an anti-interleukin-33 receptor (IL-33R) monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis...
7.
Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K, et al.
Blood Adv
. 2020 Mar;
4(5):906-919.
PMID: 32150609
CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that...
8.
Akpalu D, Frederick B, Nnane I, Yao Z, Shen F, Ort T, et al.
J Clin Pharmacol
. 2019 Feb;
59(7):968-978.
PMID: 30776134
The safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of JNJ-61178104, a novel anti-tumor necrosis factor-alpha (TNFα) and anti-interleukin-17A (IL-17A) bispecific antibody, were investigated in a placebo-controlled, first-in-human study. Healthy subjects (n ...
9.
Cowan K, Amaravadi L, Cameron M, Fink D, Jani D, Kamat M, et al.
AAPS J
. 2017 Oct;
19(6):1550-1563.
PMID: 28971363
As biomarkers continue to become an integral part of drug development and decision-making, there are increased expectations for reliable and quantitative assays. Protein biomarker assay results are directly influenced by...
10.
Wang W, Wang X, Doddareddy R, Fink D, McIntosh T, Davis H, et al.
AAPS J
. 2013 Nov;
16(1):129-39.
PMID: 24287601
For therapeutic monoclonal antibodies (mAbs) against soluble ligands, the free ligand level can, theoretically, be used as a surrogate for efficacy. However, it can be extremely challenging technically to measure...